These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 5364658)

  • 21. [Present-day treatment of parkinsonism in the aged].
    Siegfried J
    Schweiz Rundsch Med Prax; 1973 Oct; 62(40):1202-3. PubMed ID: 4754539
    [No Abstract]   [Full Text] [Related]  

  • 22. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E; Cerillo A; Tata MR; Decina A
    Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
    [No Abstract]   [Full Text] [Related]  

  • 23. Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
    Messiha FS; Hsu TH; Bianchine JR
    J Clin Invest; 1972 Feb; 51(2):452-5. PubMed ID: 5009125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Attempt at treating parkinsonism with L-dopa and Artane].
    Stelmasiak Z; Lackowska H; Maksymowicz B
    Pol Tyg Lek; 1971 Aug; 26(34):1325-6. PubMed ID: 5110789
    [No Abstract]   [Full Text] [Related]  

  • 25. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B; Steinhäusl H
    Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
    [No Abstract]   [Full Text] [Related]  

  • 26. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
    Steinhäusl H
    Wien Med Wochenschr; 1973 Jun; 123(26):433-5. PubMed ID: 4578743
    [No Abstract]   [Full Text] [Related]  

  • 27. [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].
    Schneider E; Fischer PA; Jacobi P; Maxion H
    Arch Psychiatr Nervenkr (1970); 1973 Mar; 217(1):95-112. PubMed ID: 4695662
    [No Abstract]   [Full Text] [Related]  

  • 28. [Familial syndrome with parkinsonian tremor and anosmia and its therapy with L-dopa associated with a decarboxylase inhibitor].
    Constantinidis J; de Ajuriaguerra J
    Therapeutique; 1970 Mar; 46(3):263-9. PubMed ID: 5422192
    [No Abstract]   [Full Text] [Related]  

  • 29. [Association of L-dopa and other therapeutic methods in treatment of parkinsonian syndromes].
    Mingrino S
    Sist Nerv; 1970; 22(2):212-5. PubMed ID: 4926920
    [No Abstract]   [Full Text] [Related]  

  • 30. Therapeutic guidelines and side effects encountered during L-dopa therapy in 100 cases of parkinsonism.
    Jenkins AC; Schwieger AC
    Med J Aust; 1971 Oct; 2(14):693-700. PubMed ID: 5114186
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 32. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
    Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R
    Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects].
    Geissbuhler F; Eisenring JJ; Friedli P; Bartholini G; Tissot R
    Encephale; 1972; 61(2):127-48. PubMed ID: 4634903
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 35. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J
    Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970
    [No Abstract]   [Full Text] [Related]  

  • 36. [Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) (author's transl)].
    Eisenlohr JJ; Gehlen W
    MMW Munch Med Wochenschr; 1974 Jul; 116(28):1353-6. PubMed ID: 4212699
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of Parkinson's disease: L-dopa or stereotaxic technics?].
    Krayenbuhl H; Siegfried J
    Neurochirurgie; 1970; 16(1):71-6. PubMed ID: 4911157
    [No Abstract]   [Full Text] [Related]  

  • 38. [Cardiovascular effects of L-dopa and decarboxylase inhibitor on patients with Parkinson's disease].
    Desjacques P; Moret P; Gauthier G
    Schweiz Med Wochenschr; 1973 Dec; 103(50):1783-5. PubMed ID: 4129257
    [No Abstract]   [Full Text] [Related]  

  • 39. [Combined therapy of parkinsonism with bromocriptine, L-dopa and decarboxylase inhibitor (author's transl)].
    Vardy J; Rabey JM; Streifler M
    Harefuah; 1977 Sep; 93(5-6):129-33. PubMed ID: 924233
    [No Abstract]   [Full Text] [Related]  

  • 40. [Accomplishment of the treatment and evaluation of treatment alternatives in parkinsonism].
    Presthus J
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2119. PubMed ID: 4773985
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.